Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimethyl fumarate versus placebo for perioperative neurosurgical brain injury in glioblastoma
IRCT20200226046624N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in glioblastoma (GBM) comparing Dimethyl fumarate plus routine treatment with Placebo plus routine treatment (2 arms). Primary endpoints: Karnofsky performance score and Peripheral blood S100 beta protein concentration. Started Mar 2018; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on IRCT20200226046624N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200226046624N1.